● Recruiting

CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence

Condition: Biliary Tract Cancer · Cholangiocarcinoma · Sponsor: Gruppo Oncologico del Nord-Ovest

PhasePhase 2/Phase 3

Planned participants300

Who can joinAll sexes, 18 Years to 75 Years

Healthy volunteersNo

About this study

PURITY is a multicentre, randomized adaptive phase II/III trial aimed at comparing the triplet combination of gemcitabine, cisplatin and nabpaclitaxel as neoadjuvant treatment (ARM A) versus standard upfront surgery (ARM B) in terms of 12-month PFS rate (phase II part) and PFS (phase III part) in patients with resectable BTC at high risk for recurrence.

This description comes directly from the study's public registry record.

Talk to the study team

Monica Niger, MD · 02 2390 2919 · monica.niger@istitutotumori.mi.it

Federico Nichetti, MD · 02 2390 3586 · PURITYstudy@istitutotumori.mi.it

Always discuss trial participation with your own doctor first.

Locations (19)

Ospedali Riuniti di Ancona	Ancona, Italy	Not Yet Recruiting
ASST Papa Giovanni XXIII	Bergamo, Italy	Not Yet Recruiting
Oncologia Medica Policlinico Sant'Orsola - Malpighi	Bologna, Italy	Not Yet Recruiting
ASST Spedali Civili	Brescia, Italy	Not Yet Recruiting
Azienda Ospedaliera S. Croce e Carle	Cuneo, Italy	Not Yet Recruiting
IRST Dino Amadori	Meldola, Italy	Not Yet Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan, Italy	Recruiting
Humanitas Cancer Center	Milan, Italy	Not Yet Recruiting
Ospedale Niguarda Cancer Center	Milan, Italy	Not Yet Recruiting
Ospedale San Raffaele	Milan, Italy	Not Yet Recruiting
Università di Modena	Modena, Italy	Not Yet Recruiting
Ospedale S. Gerardo	Monza, Italy	Not Yet Recruiting

+ 7 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06037980